Clopidogrel and the Newer P2y12 Antiplatelet Agents: Pharmacology, Clinical Uses, and Adverse Effects-Original PDF

Clopidogrel and the Newer P2y12 Antiplatelet Agents: Pharmacology, Clinical Uses, and Adverse Effects-Original PDF

Login is required

login

If you are not our user, for invitation Click Here

Amazon Price $286

By Michael P. Savage(Editor), David L., M.d. Fischman(Editor)

Size : 6.38 MB

This book examines virtually all aspects of P2Y12 inhibitors – pharmacology, clinical uses, randomized trial results, guideline recommendations, and adverse drug effects. Important fundamental issues are reviewed including comparative pharmacology of P2Y12 inhibitors, randomized trials of clopidogrel in patients with coronary artery disease, DAPT duration after PCI, and role of platelet function testing. The newer P2Y12 inhibitors (prasugrel, ticagrelor, and cangrelor) receive special focus. Use of antiplatelet therapy in specific patient populations is discussed including patients with coronary bypass graft surgery, peripheral vascular disease, cerebrovascular disease, and structural heart disease. Management of antiplatelet therapy in patients who require anticoagulation is a particularly challenging clinical setting and is the topic of a featured review. Finally, adverse drug effects and reactions are examined in a section highlighting clopidogrel resistance, clopidogrel hypersensitivity, and bleeding complications.

Product Details

  • Series: Cardiology Research and Clinical Developments
  • Hardcover: 308 pages
  • Publisher: Nova Science Pub Inc (March 19, 2019)
  • Language: English
  • ISBN-10: 1536149721
  • ISBN-13: 978-1536149722